centromeric cohesin might be the major target of protection from degradation at anaphase I. Given that pericentromeric Rec8 is dispensable for the monopolar attachment, Rec8 bound to the centromeric central core could be responsible for this role at meiosis I (Fig. 4) , as predicted in our previous model (6, 20) .
Previous studies have established that the cohesin complex in meiosis is different from that in mitosis. Our findings indicate that the species of cohesin complex also varies with location along the chromosome, thereby organizing distinct chromosome domains. Mammals have at least three Scc3-like proteins, STAG1-3/SA1-3. STAG3 is meiosis-specific, localizing along chromosome arms during meiotic prophase I but becoming undetectable thereafter (25) , indicating that STAG3 is most likely an ortholog of Rec11. Drosophila also has a meiosis-specific Scc3-like protein (26) , suggesting the conservation of this principle. During mitosis, a substantial release of cohesin from chromosome arms accompanies the process of chromosome condensation, producing two recognizable chromatids (27) . Nonetheless, important levels of cohesin remain, especially at centromeres, until the onset of anaphase. Cohesin enrichment at centromeres during mitosis is mediated through an interaction between cohesin and heterochromatin in fission yeast and also, presumably, in mammals (18, 28) . This system might be insufficient for the more complex process of meiosis, as cohesion along chromosome arms plays a crucial role in promoting recombination and holding homologs tightly together to ensure disjunction at meiosis I. Thus, the meiosis-specific cohesin subunit Rec11/STAG3 might have evolved to strengthen or develop the arm function of cohesin. We have shown that defects in the armspecific Rec11-associated cohesin cause meiosis I nondisjunction. This phenotype differs markedly from the more disruptive chromosome segregation seen in rec8⌬. Therefore, such arm-specific cohesion factors may be particularly important to consider with regard to human reproductive problems like Down syndrome, which arises mainly from nondisjunction in meiosis I. About 50% of cancer patients receive radiation therapy. Here we investigated the hypothesis that tumor response to radiation is determined not only by tumor cell phenotype but also by microvascular sensitivity. MCA/129 fibrosarcomas and B16F1 melanomas grown in apoptosis-resistant acid sphingomyelinase (asmase)-deficient or Bax-deficient mice displayed markedly reduced baseline microvascular endothelial apoptosis and grew 200 to 400% faster than tumors on wild-type microvasculature. Thus, endothelial apoptosis is a homeostatic factor regulating angiogenesis-dependent tumor growth. Moreover, these tumors exhibited reduced endothelial apoptosis upon irradiation and, unlike tumors in wild-type mice, they were resistant to single-dose radiation up to 20 grays (Gy). These studies indicate that microvascular damage regulates tumor cell response to radiation at the clinically relevant dose range.
Ionizing radiation is a widely used therapy for solid tumors and is thought to act by directly targeting tumor clonogens, also known as stem cells (1, 2) . Tumor curability is believed to be determined by the most resistant clonogen, because one surviving stem cell appears sufficient for reconstituting tumor growth (3, 4) . This model appears relevant to several normal tissues, particularly those classified as rapid-turnover systems.
For example, gastrointestinal (GI) damage is believed to result from direct interaction of radiation with the clonogenic compartment at the crypt of Lieberkühn base (5, 6) . However, we recently reported that microvascular endothelial apoptosis is required for clonogenic cell dysfunction (7) . GI damage was prevented when endothelial cell apoptosis was inhibited genetically by asmase -/-depletion or pharmacologically by intravenous basic fi- broblast growth factor (bFGF) (7) (8) (9) . Because endothelial cells, but not crypt cells, expressed bFGF receptors, GI protection afforded by bFGF appeared to result from prevention of microvascular dysfunction. The notion that the microvasculature, rather than the clonogenic component, might be the primary target for radiation provides a basis for exploring new mechanisms of radiation effects on tumors.
The important role of the microvasculature in controlling tumor growth is well established. Tumors are considered to be growing near their maximal growth rate (2) because they purportedly limit their own growth by regulating neoangiogenesis (10 fig. S1 ) and B16F1 melanomas implanted into asmase -/-mice (Fig. 1A , lower panel). To evaluate whether these differences correlated with the apoptotic competence of the host endothelium, we first determined (using hematoxylin, anti-CD34 immunohistochemical staining for endothelium, and morphological criteria) that MCA/129 tumors at 8 days after implantation contained 35 Ϯ 2 endothelial cells and 1200 Ϯ 38 fibrosarcoma cells per 400ϫ field. Double staining with anti-CD34 and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL), as described (7, 13) , revealed that when fibrosarcomas were implanted into asmase ϩ/ϩ mice, baseline endothelial apoptosis was increased by a factor of 2.4 relative to asmase -/-mice (6.1 Ϯ 0.6 versus 2.5 Ϯ 0.3 apoptotic endothelial cells per 400ϫ field, respectively; P Ͻ 0.01) (Fig. 2B) .
To assess whether the radiosensitivity of MCA/129 fibrosarcomas and B16F1 melanomas also depends on host asmase, we irradiated tumors with doses from 10 to 20 Gy. Exposure of fibrosarcomas grown in wildtype mice to 10 Gy caused a growth delay of 9 Ϯ 1 days and 10% tumor control [TCD 10 , established as in (14)] but did not affect tumors implanted into asmase -/-mice ( fig.  S2 ; P Ͻ 0.01 versus asmase ϩ/ϩ ). At 15 Gy (Fig. 1B) , fibrosarcomas in wild-type mice continued to grow for 2 to 3 days after irradiation, but thereafter displayed a 69 Ϯ 5% reduction in size (P Ͻ 0.001 versus day 9). Analysis of individual mice for up to 120 days showed that this dose conferred 50% tumor control ( TCD 50 ). In contrast, these tumors appeared completely resistant to 15 Gy when implanted in asmase -/-mice (P Ͻ 0.01 versus asmase ϩ/ϩ ), continuing to grow at a rate not significantly different from that of unirradiated controls. Exposure to 20 Gy, however, appeared to overcome the radioresistance of tumors growing in asmase -/-mice, as tumors in both genetic backgrounds manifested a similar 80% volume reduction by 1 week after irradiation ( fig. S3 ). B16F1 melanomas were also sensitive to 15 Gy when implanted in asmase ϩ/ϩ mice, showing a 40% reduction in volume after 1 week (P Ͻ 0.01 versus unirradiated), but were resistant when grown in asmase -/-mice (15). To determine whether differences in tumor response to radiation correlated with induction of endothelial apoptosis, we stained tumor tissue specimens with TUNEL and anti-CD34 after exposure to 15 Gy (13). MCA/129 fibrosarcomas in asmase ϩ/ϩ mice displayed markedly increased endothelial apoptosis beginning at 1 hour and peaking at 4 to 6 hours (17.5 Ϯ 1.3 apoptotic endothelial cells per 400ϫ field at 6 hours; P Ͻ 0.01 versus unirradiated) (Fig. 2B ). Typical histologic fields at 4 hours after irradiation are shown in the upper panel of Fig. 2A . Minimal tumor cell apoptosis was detected subsequent to endothelial cell apoptosis, increasing to less than twice the baseline value of 4.2 Ϯ 0.7 apoptotic tumor cells per 400ϫ field at 6 to 10 hours after irradiation. Thus, 50% of the endothelial cells but only 0.35% of tumor cells underwent apoptosis within this time frame. In contrast, endothelium of tumors in asmase -/-mice was resistant to radiationinduced apoptotic death ( and asmase -/-mice. Cells (10 6 , resuspended in phosphate-buffered saline) were injected subcutaneously into the right hindlimb, and tumor volume (based on caliper measurements) was calculated daily according to the formula of Kim et al. (30) . (B) MCA/129 fibrosarcomas implanted as in (A) were treated with 15 Gy at a volume of 100 to 150 mm 3 . Mice, lightly sedated with ketamine (0.1 mg/g) and xylazine (0.02 mg/g), were irradiated using a Philips MG-324 x-ray unit at 105.5 cGy/min (source-to-skin distance, 50 cm). Only tumor, surrounding skin, and subcutaneous tissues were exposed; the rest of the mouse was shielded with a specialized lead jig. Values are means Ϯ SEM. Numbers of mice are in parentheses. Arrow indicates day of irradiation.
of an alternative tumor response mechanism at the higher dose range.
To confirm that apoptosis resistance of the endothelium confers enhanced tumor growth and reduced radiation responses, we performed studies with mice null for Bax, a proapoptotic Bcl-2 family member (16) . Previous studies in asmase -/-and Bax -/-mice indicate that these genes function in the same antiapoptotic pathway in oocytes (17) . B16F1 melanomas implanted in Bax -/-mice grew faster than in Bax ϩ/ϩ littermates by a factor of 4 to 5 (Fig. 2C) . Further, as occurred with asmase -/-mice, the tumors manifested marked reductions in baseline and radiationinduced endothelial cell apoptosis as well as in tumor radiation response ( fig. S5) .
We next tested whether asmase -/-bone marrow (BM) transplantation confers increased tumor proliferation and radioresistance. Recent studies showed that BMderived VEGFR2-positive endothelial precursor cells contribute to rapid tumor neoangiogenesis (18) . To assess whether the microvasculature of MCA/129 fibrosarcomas is derived from circulating BM precursors, we treated wild-type mice with 12 Gy wholebody irradiation (WBR) to sterilize the BM (7) Figs. 3A and 1A) , consistent with the known reduction in stem cell capacity that accompanies BM transplantation (19) . Tumors grown in wild-type mice reconstituted with asmase -/-BM became resistant to 15 Gy ( Fig.  3B ; P Ͻ 0.01 versus tumors in mice reconstituted with asmase ϩ/ϩ BM). Similar data were obtained with B16F1 melanoma (15) . Additionally, radioresistance was observed with any combination in which transplanted BM was asmase -/-, irrespective of the genotype of the host, and vice versa for asmase ϩ/ϩ BM (15). Furthermore, transplantation of rag -/-; asmase ϩ/ϩ BM had no effect on tumor growth or radiation responsiveness, which suggests that the effects of loss of asmase were not due to defective immune responses (15) .
We next investigated whether resistance of asmase -/-endothelium to radiation-induced apoptosis in tumor tissue was due to direct loss of asmase within endothelium rather than to a systemic factor. MCA/129 fibrosarcomas were excised from mice, placed in Dulbecco's modified Eagle's medium (DMEM) supplemented with 0.2% fetal bovine serum at 37°C, and irradiated ex vivo with 15 Gy. Exposure of tumors containing asmase ϩ/ϩ vasculature to 15 Gy ex vivo resulted in time-dependent endothelial cell apoptosis (Fig. 4A ) similar to that observed in tumors irradiated in vivo (P Ͻ 0.001 versus unirradiated asmase ϩ/ϩ controls at 2 to 4 hours). In contrast, tumors populated by asmase -/-endothelium irradiated ex vivo were resistant to radiation-induced apoptosis (P Ͻ 0.001 versus tumors excised from asmase ϩ/ϩ mice at 2 to 4 hours after irradiation). Because it remained possible that another asmase -/-cell type derived from the host and infiltrating the tumor might regulate the endothelial response even in tumors irradiated ex vivo, we purified tumor endothelial cell populations of greater than 95% purity by a modification of the approach of Kinzler and co-workers ( fig. S7 ) (20) and subjected them to irradiation. At 15 Gy, isolated asmase ϩ/ϩ tumor endothelial cells underwent time-dependent apoptosis peaking at 8 hours ( fig. S8 ; P Ͻ 0.01 versus control). In contrast, asmase -/-tumor endothelium was largely radioresistant (P Ͻ 0.001 versus irradiated asmase ϩ/ϩ at 4 to 8 hours). Figure 4B shows full dose-response profiles of this effect 8 hours after irradiation. These studies show a maximal 63 Ϯ 3% apoptosis at 25 Gy in asmase ϩ/ϩ tumor endothelial cells (P Ͻ 0.001 versus unirradiated). In contrast, asmase -/-tumor endothelium was almost entirely resistant to ionizing radiation-induced apoptotic death (P Ͻ 0.001 versus asmase ϩ/ϩ from 11 to 25 Gy). Our results add to previous genetic evidence that tumors are angiogenesis dependent (21) , defining the occurrence of endothelial apoptosis in the tumor microvasculature as a critical homeostatic factor regulating the rate of tumor growth (13, 22, 23) . The striking apoptotic sensitivity of asmase ϩ/ϩ endothelium is consistent with endothelium synthesizing 20 times as much ASMase as any other cell in the body, mostly in a nonlysosomal secretory form (24) . The large excess of ASMase in endothelium may be involved in tissue remodeling and wound repair (25) , events normally requiring waves of tissue neoangiogenesis and endothelial apoptosis (26) . This suggests that a normal function of endothelial ASMase is to delimit rapid growth associated with tumor development.
Our studies define a similar pattern of tissue response in the GI tract and tumorsthat is, rapid endothelial apoptosis followed over a period of days by tissue regressionwhich suggests that sustained microvascular dysfunction regulates tumor stem cell dysfunction in response to low-dose irradiation. This paradigm diverges from the current consensus that DNA damage and mitotic death, resulting from direct interaction of radiation with tumor cells, is an autonomous mechanism by which radiation confers its antitumor effect. That the radioprotective effect likely resulted from direct protection of tumor endothelium was confirmed here by isolating pure asmase -/-endothelial cell populations resistant to as much as 25 Gy.
If the microvasculature is a target for therapy, why has it been so difficult to establish this principle clinically? We believe the answer resides in the notion that endothelial apoptosis in tissue (and cell culture) is subject to transmodulation. Different tumors likely secrete growth factors, cytokines, and mitogens that differ in type and amount according to genetic factors (e.g., tumor cell type, mutations) as well as epigenetic factors (e.g., hypoxia, nutritional status), and these secretions would tend to modify the radiosensitivity of their endothelial cells (27 ) . Thus, tumors may regulate the baseline apoptotic level and the radioresponsiveness of their own microvascular endothelium.
Our data define microvascular damage as a key mechanism in tumor response to radiation at the low dose range. This dose range is equivalent in its biological effects to the higher dose levels delivered clinically with daily fractionated radiotherapy schemes (28) . In this context, antibodies to VEGFR2 sensitize human small cell lung carcinoma and glioblastoma xenografts in nude mice to fractionated radiotherapy (14) , which suggests microvasculature involvement in this response (13, 29) . Our studies also identify the sphingomyelin pathway as a possible target for improving cancer treatment, perhaps by manipulating asmase levels in tumor endothelial cells or in endothelial precursors. S7 ) from MCA/129 fibrosarcomas implanted in asmase ϩ/ϩ mice are more radiosensitive than those isolated from asmase -/-mice. A minimum of 500 cells, stained with bis-benzimide, were scored for apoptosis at each dose 8 hours after irradiation, as described (33) . Data (means Ϯ SEM) were collated from three independent experiments.
After formation of each peptide bond, ribosome-bound tRNAs are translocated, by distances of 20 Å or more (1), to their adjacent sites in the ribosome, with the coupled movement of mRNA by one codon. Elongation factor G (EF-G) catalyzes translocation, hydrolyzing guanosine triphosphate (GTP) in the process. However, under certain in vitro conditions, translocation has been observed in the absence of EF-G and GTP (2) (3) (4) (5) , implying that translocation can proceed spontaneously and is a function embodied in the ribosome itself.
The directionality of translocation is determined at least in part by the chemical specificity of each tRNA binding site in the ribosome. The aminoacyl (A) site has the highest affinity for aminoacyl-tRNA, the peptidyl (P) site for peptidyl-tRNA, and the exit (E) site for deacylated tRNA (6) (7) (8) . During protein synthesis, once aminoacyl-tRNA enters the ribosomal A site, peptide-bond formation occurs. This results in transfer of the peptide chain from the P-site tRNA to the A-site tRNA and thus a change in the acylation state of both tRNA molecules; the P-site tRNA becomes deacylated and the A-site tRNA becomes linked to a peptidyl group rather than an aminoacyl group. In vitro chemical probing experiments have shown that the tRNA molecules in the ribosome are then able to move spontaneously with respect to the 50S subunit, resulting in the formation of a hybrid state complex (9) . Thus, the peptidyl-tRNA occupies the 30S A site and 50S P site (the A/P state), whereas the deacylated tRNA occupies the 30S P site and 50S E site (the P/E state) (Fig. 1A) . Formation of the hybrid state complex makes the subsequent translocation reaction thermodynamically more favorable and contributes to the kinetics of translocation by decreasing the free energy of activation (10) . However, the free energy barrier remains substantial, and typically, spontaneous translocation in the absence of EF-G is very slow or not observed. Interaction of EF-G with the pretranslocation complex promotes rapid translocation, presumably by inducing conformational changes in the ribosome that further decrease the free energy barrier.
The acylation states of tRNA molecules in the ribosome affect not only the energetics of translocation but also its accuracy. When deacylated tRNA or aminoacyl-tRNA is translocated to the P site by EF-G, movement of tRNA and mRNA often becomes uncoupled, resulting in a repositioned translational reading frame. In contrast, when peptidyl-tRNA (or its analog N-acetyl-aminoacyl-tRNA) is translocated in the same context, mRNA movement is accurately coupled (11) . Because interactions between the acylated end of tRNA and the peptidyl transferase center (PTC) of the 50S subunit appear to influence translocational accuracy, we tested several peptidyl transferase inhibitors for their effect on translocation. Although none of those tested affected accuracy, we found that sparsomycin induces translocation by the ribosome in the absence of EF-G and GTP (Fig. 1) . When tRNA 2 Tyr (1 M) and message m301 (1 M) are bound to ribosomes (0.7 M), a prominent toeprint is observed at ϩ16 (Fig. 1C, lane 1) . This ϩ16 toeprint indicates that the anticodon of tRNA 2 Tyr , bound to the 30S P site, is paired with the UAC tyrosine codon (designated as codon 1) positioned 10 nucleotides downstream from the ShineDalgarno sequence (Fig. 1B) . Binding of Nacetyl-Phe-tRNA Phe (1 M) to codon 2 (UUU) in the 30S A site results in an additional toeprint at ϩ17 (Fig. 1C, lane 2) , characteristic of A-site binding (12) . Addition of either EF-G (at 1 M with 300 M GTP) or sparsomycin (500 M) results in a shift of the ϩ16/17 toeprints to ϩ19 (Fig. 1C, lanes 4 and 6) . The toeprint at ϩ19 indicates movement of the mRNA by three nucleotides relative to the small ribosomal subunit, yielding a posttranslocation complex containing N-acetyl-Phe-tRNA Phe paired to codon 2 (UUU) in the 30S P site. Thus, sparsomycin promotes efficient translocation of m301 with N-acetyl-Phe-tRNA Phe . In control experiments, addition of sparsomycin to ribosomal complexes that contained only P-site N-acetyl-aminoacyl-tRNA caused no change of the toeprint (13) . To our knowledge, this is the first example of a factor other than EF-G able to catalyze ribosomal translocation.
The accuracy of translocation can be assessed in vitro if the mRNA sequence contains
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